Century-old TB vaccine shows promise in reducing insulin use for diabetes patients
A phase II clinical trial found that the BCG vaccine, developed in the 1920s to prevent tuberculosis, helped people with autoimmune diabetes reduce their insulin use by an average of 3% over five years. The vaccine works by stimulating the immune system to protect insulin-producing cells in the pancreas from autoimmune attack. This finding supports the hypothesis that certain vaccines can provide benefits beyond their original target disease and may open new treatment approaches for diabetes.
Researchers led by Denise Faustman at Massachusetts General Hospital conducted a trial testing the Bacillus Calmette–Guérin (BCG) vaccine as a treatment for autoimmune diabetes. The study enrolled 95 people with latent autoimmune diabetes in adults (LADA), with 68 receiving six BCG shots over five years and others receiving placebos. While the vaccine did not lower blood sugar levels directly, it reduced insulin use by approximately 3% in the treatment group, whereas the placebo group's insulin use increased by 22% over the same period. The results suggest the vaccine protects insulin-producing β-cells from autoimmune deterioration. This finding adds to growing evidence that the BCG vaccine, already FDA-approved for bladder cancer treatment, may have broader therapeutic applications beyond tuberculosis prevention, including potential benefits for Alzheimer's disease and other conditions.
What's missing
The article does not discuss potential side effects or safety concerns of using the BCG vaccine in diabetic populations, nor does it address the timeline for potential clinical availability or regulatory pathways for approval as a diabetes treatment. Additionally, there is limited discussion of why this mechanism works or what makes the BCG vaccine uniquely suited for this application compared to other immune-stimulating approaches.
How coverage differed
The Nature News article presents the findings in a straightforward, scientifically rigorous manner with expert commentary supporting the results. The framing emphasizes the novelty and potential significance of the discovery while maintaining appropriate scientific caution about the modest effect size (3% reduction in insulin use).
What different sources said
- Nature NewsCenter
TB vaccine from the 1920s shows promise in diabetes trial
Related
WHO and Africa CDC Launch $518 Million Emergency Response to Ebola Outbreak
The World Health Organization and Africa Centres for Disease Control and Prevention announced a $518 million joint emergency response program to combat an ongoing Ebola outbreak primarily affecting Congo and Uganda. The six-month initiative, following a unified "One-Response" approach, comes as case numbers continue to rise despite earlier WHO estimates suggesting fewer cases than previously thought. The response is significant because the current Bundibugyo strain has a 25-50% fatality rate and no approved targeted treatments exist, making coordinated international action critical.
People increasingly turn to AI chatbots for health information, revealing gaps in healthcare access
A new study published in Nature Health examines how people are using AI chatbots to answer health and wellness questions, highlighting a trend of seeking medical information through artificial intelligence. This reflects broader challenges in healthcare accessibility and the quality of health information available online. The findings raise important questions about the responsibilities of AI companies in providing accurate health guidance and the adequacy of traditional healthcare provision.
UK Government Proposes Updates to School Food Standards to Reduce Unhealthy Options
The UK government is proposing changes to school food standards that would remove deep-fried foods and fruit juice while limiting pizza availability. The updates aim to increase fiber content and reduce fat, sugar, and salt in meals served to secondary school students. The changes reflect growing concerns about student nutrition and dietary health in educational settings.